Thr105

Site Information
sAAVLRLtGrGGGGt SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 34349107

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 )
Disease tissue studied:	brain cancer ( 2 ) , glioblastoma ( 2 ) , glioma ( 2 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 1 ) , acute megakaryoblastic leukemia (M7) ( 1 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 1 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 1 ) , acute myeloblastic leukemia, without maturation (M1) ( 1 ) , B cell lymphoma ( 1 ) , non-Hodgkin's lymphoma ( 1 ) , multiple myeloma ( 1 )
Relevant cell line - cell type - tissue:	AML-193 (monocyte) ( 1 ) , CMK (megakaryoblast) ( 1 ) , CTS (myeloid) ( 1 ) , DOHH2 ('B lymphocyte, precursor') ( 1 ) , HEL (erythroid) ( 1 ) , Kasumi-1 (myeloid) ( 1 ) , KG-1 (myeloid) ( 1 ) , M059K (glial) ( 2 ) , MV4-11 (macrophage) ( 1 ) , OPM-2 (plasma cell) ( 1 ) , P31/FUJ (erythroid) ( 1 ) , RL ('B lymphocyte, precursor') ( 1 ) , RPMI-8266 (plasma cell) ( 1 ) , SU-DHL-6 (B lymphocyte) ( 1 ) , U266 (plasma cell) ( 1 )

References
1	Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37 23628362 Curated Info
2	Stokes M (2007) CST Curation Set: 2262; Year: 2007; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info